PharmaLundensis AB   Report issue

For profit Phase 2
Founded: Lund Sweden (2006)
Status: No NME R&D (2006)

Organization Overview

First Clinical Trial
2011
NCT01404000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

Iodopropynyl Butyl Carbamate (1 trial)

medicinal charcoal (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatigue (Phase 2)

Fatigue Syndrome, Chronic (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2